This patient is NEDA-2 (no relapses or MRI activity), but is getting worse on DMF (Tecfidera). She has smouldering MS. Do I label her as having SPMS and switch her to siponimod (Mayzent), or not?
Dear professor, can her disease activity be proved via lumbar puncture and then she can continue to be treated as a case of active MS and therefore qualify to receive Siponimod or any other DMT that might be appropriate for her?
Dear professor, can her disease activity be proved via lumbar puncture and then she can continue to be treated as a case of active MS and therefore qualify to receive Siponimod or any other DMT that might be appropriate for her?
Prof. Gavin
Is there any data ( or from your experience) for patients who use the Siponimod showing improvement on EDSS.
Why not keeping this patient classified as RRMSer and offer her Lemtrada or Cladribine the switch to Siponomod in a few years?